Merck, Xeris announce collaboration agreement

Monday, 25. October 2021 13:51

Merck & Co. and Xeris Biopharma Holdings, Inc. announced a collaboration agreement on Monday with an option to licence XeriJect, Xeris' suspension-based formulation technology.

"We are quite excited to be working closely with Merck on this opportunity using our novel platform technology, XeriJect ... The XeriJect platform has broad applicability in improving the delivery of large molecules, such as monoclonal antibodies. This is another in a series of collaborations Xeris has undertaken with top 10 pharma companies evaluating the XeriJect technology" Xeris CEO Paul R. Edick said.

The terms of the agreement have not been disclosed.

Related Links: Merck & Co. Inc.
Breaking the News / IB